Edgewise Therapeutics, Inc.

NASDAQ•EWTX

CEO: Dr. Peter A. Thompson FACP, M.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-03-26

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

連絡先情報

1715 38th Street, Boulder, CO, 80301, United States

720-262-7002

www.edgewisetx.com

時価総額

$3.06B

PER (TTM)

-17.7

19.7

配当利回り

52週高値

$31.82

52週安値

$10.60

52週レンジ

86%

順位53Top 76.1%

2.8

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.8 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.47+0.00%

直近4四半期の推移

フリーCF

-$38.41M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Widens Substantially Net loss reached $167.8M USD in 2025, up $34.0M from 2024; total operating expenses increased $32.6M to $191.4M USD.

R&D Spending Ramps Up Research and development expenses totaled $151.4M USD in 2025, increasing $24.4M, driven by sevasemten and EDG-7500 clinical activities.

Cash Position Maintained Cash, equivalents, and securities totaled $530.1M USD as of December 31, 2025, supported by recent registered direct offerings.

Pipeline Advancement Continues Sevasemten trials ongoing in Becker/Duchenne; EDG-7500 in multipart Phase 2 HCM trial; EDG-15400 entered Phase 1.

リスク要因

High Operating Losses Continue Incurred $167.8M USD net loss for 2025; no revenue generated to date; expects significant losses for foreseeable future.

Need Substantial Additional Capital Substantial additional capital required to fund operations; failure to raise funds delays development or eliminates research programs.

Clinical Development Outcome Uncertain Clinical trial results are uncertain; success of lead candidates sevasemten and EDG-7500 substantially impacts business viability.

Competition Threatens Market Share Faces significant competition from established firms; competitors developing safer, more effective, or less expensive therapies.

見通し

Advance Key Clinical Programs Continue advancing sevasemten in muscular dystrophies and EDG-7500 in HCM through ongoing and planned clinical trials.

Initiate EDG-15400 Phase Two Plans to initiate Phase 2 trial for EDG-15400 in HFpEF patients in the second half of 2026, following Phase 1 completion.

Expect Increased Operating Expenses Anticipates general and administrative expenses will increase as organization scales to support clinical advancement and regulatory readiness.

Secure Future Capital Requirements Future funding needs depend on R&D progress, regulatory review costs, and market conditions; substantial additional funding required.

同業比較

売上高 (TTM)

GLPG

$1.26B

+303.5%

NVAX

$1.12B

+64.7%

HRMY

$868.45M

+21.5%

粗利益率 (最新四半期)

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

NUVB

99.0%

+182.9pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
EWTX	$3.06B	-17.7	-32.0%	0.7%
VERA	$2.81B	-8.5	-59.7%	10.5%
WVE	$2.55B	-12.1	-85.0%	2.8%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月6日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし